Back

One- versus three-month dual antiplatelet therapy in high-bleeding-risk patients undergoing PCI: a bayesian and trial sequential meta-analysis

31 August 2026 (09:09 - 09:27)
Organised by: Logo
Congress Presentation Part of: Percutaneous coronary intervention and adjunctive therapeutic strategies Stent Thrombosis ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Kunal Mahajan

Himachal Heart Institute, Mandi (India)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on percutaneous coronary intervention and adjunctive therapeutic strategies
Doctor G. Stone (New York City, US)
Presentation thumbnail
Temporal trends and outcomes of superelderly patients undergoing coronary intervention with and without acute myocardial infarction: Insights from the Japanese nationwide registry
Mr Y. Saito (Chiba, JP)
Abstract
Presentation thumbnail
Drug-coated balloons angioplasty versus drug-eluting stents for coronary artery bypass graft
Doctor T. Aikawa (Tokyo, JP)
Abstract
Presentation thumbnail
Dual impairment of thrombotic and fibrinolytic pathways assessed by the global thrombosis test predicts adverse clinical outcomes after percutaneous coronary intervention
Professor J. Suh (Seongnam, KR)
Abstract

Access the full session

Session thumbnail
Percutaneous coronary intervention and adjunctive therapeutic strategies

The Event

Event poster

ESC Congress 2026

31 August 2026 09:09 CET
You may be interested in
thumbnail
Congress Presentation
Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: a systematic review and meta-analysis
27 August 2022
thumbnail
Congress Presentation
Comparative efficacy and safety of antithrombotic regimens following left atrial appendage occlusion therapy in atrial fibrillation patients: a comprehensive Bayesian network meta-analysis
4 April 2025
thumbnail
Congress Presentation
Implications of ESC-high tthrombotic risk features and ARC-high bleeding risk criteria on clinical outcomes in all-comer patients undergoing PCI
29 August 2021
thumbnail
Congress Presentation
The effect of P2Y12 inhibitor pretreatment vs. no pretreatment on major bleeding among patients with NSTE-ACS: an updated meta-analysis and meta-regression pooling 41,548 patients from 11 studies
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources